0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evaluation of cellular water exchange in a mouse glioma model using dynamic contrast-enhanced MRI with two flip angles

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This manuscript aims to evaluate the robustness and significance of the water efflux rate constant ( k io ) parameter estimated using the two flip-angle Dynamic Contrast-Enhanced (DCE) MRI approach with a murine glioblastoma model at 7 T. The repeatability of contrast kinetic parameters and k io measurement was assessed by a test–retest experiment (n = 7). The association of k io with cellular metabolism was investigated through DCE-MRI and FDG-PET experiments (n = 7). Tumor response to a combination therapy of bevacizumab and fluorouracil (5FU) monitored by contrast kinetic parameters and k io (n = 10). Test–retest experiments demonstrated compartmental volume fractions ( v e and v p ) remained consistent between scans while the vascular functional measures ( F p and PS) and k io showed noticeable changes, most likely due to physiological changes of the tumor. The standardized uptake value (SUV) of tumors has a linear correlation with k io (R 2 = 0.547), a positive correlation with F p (R 2 = 0.504), and weak correlations with v e (R 2 = 0.150), v p (R 2 = 0.077), PS (R 2 = 0.117), K trans (R 2 = 0.088) and whole tumor volume (R 2 = 0.174). In the treatment study, the k io of the treated group was significantly lower than the control group one day after bevacizumab treatment and decreased significantly after 5FU treatment compared to the baseline. This study results support the feasibility of measuring k io using the two flip-angle DCE-MRI approach in cancer imaging.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Computational Radiomics System to Decode the Radiographic Phenotype

          Radiomics aims to quantify phenotypic characteristics on medical imaging through the use of automated algorithms. Radiomic artificial intelligence (AI) technology, either based on engineered hard-coded algorithms or deep learning methods, can be used to develop non-invasive imaging-based biomarkers. However, lack of standardized algorithm definitions and image processing severely hampers reproducibility and comparability of results. To address this issue, we developed PyRadiomics , a flexible open-source platform capable of extracting a large panel of engineered features from medical images. PyRadiomics is implemented in Python and can be used standalone or using 3D-Slicer. Here, we discuss the workflow and architecture of PyRadiomics and demonstrate its application in characterizing lung-lesions. Source code, documentation, and examples are publicly available at www.radiomics.io . With this platform, we aim to establish a reference standard for radiomic analyses, provide a tested and maintained resource, and to grow the community of radiomic developers addressing critical needs in cancer research.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

            Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo. The primary end point was overall survival. Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life. The median duration of survival was 20.3 months in the group given IFL plus bevacizumab, as compared with 15.6 months in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001). The median duration of progression-free survival was 10.6 months in the group given IFL plus bevacizumab, as compared with 6.2 months in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 percent and 34.8 percent (P=0.004). The median duration of the response was 10.4 months in the group given IFL plus bevacizumab, as compared with 7.1 months in the group given IFL plus placebo (hazard ratio for progression, 0.62; P=0.001). Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 percent vs. 2.3 percent) but was easily managed. The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer. Copyright 2004 Massachusetts Medical Society
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cellular adaptation to hypoxia through hypoxia inducible factors and beyond

              Molecular oxygen (O 2 ) sustains intracellular bioenergetics and is consumed by numerous biochemical reactions, making it essential for most species on Earth. Accordingly, decreased O 2 concentrations (hypoxia) is a major stressor that generally subverts life of aerobic species and is a prominent feature of pathological states encountered in bacterial infection, inflammation, wounds, cardiovascular defects, and cancer. Therefore, key adaptive mechanisms to cope with hypoxia have evolved in mammals. Systemically, these adaptations include increased ventilation, cardiac output, blood vessel growth, and circulating red blood cell numbers. On a cellular level, ATP consuming reactions are suppressed and metabolism is altered until oxygen homeostasis is restored. A critical question is how mammalian cells sense O 2 levels to coordinate diverse biological outputs during hypoxia. The best studied mechanism of response to hypoxia involves hypoxia inducible factors (HIFs), which are stabilized by low oxygen availability and control the expression of a multitude of genes, including those involved in cell survival, angiogenesis, glycolysis, and invasion/metastasis. Importantly, changes in O 2 can also be sensed via other stress pathways as well as changes in metabolite levels and the generation of reactive oxygen species (ROS) by mitochondria. Collectively, this leads to cellular adaptations of protein synthesis, energy metabolism, mitochondrial respiration, lipid and carbon metabolism as well as nutrient acquisition. These mechanisms are integral inputs into fine tuning the responses to hypoxic stress. The transcriptional response to hypoxia and the role of hypoxia inducible factors have been extensively studied. Yet, hypoxic cells also adapt to hypoxia by modulating protein synthesis, metabolism and nutrient uptake. Understanding these processes could shed light on pathologies associated with hypoxia, including cardiovascular diseases and cancer, and disease mechanisms such as inflammation and wound repair.
                Bookmark

                Author and article information

                Contributors
                karl.j.kiser@gmail.com
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                21 February 2023
                21 February 2023
                2023
                : 13
                : 3007
                Affiliations
                [1 ]GRID grid.5386.8, ISNI 000000041936877X, Department of Radiology, , Weill Cornell Medical College, ; 1300 York Avenue, New York, NY 10065 WMC Box 141, USA
                [2 ]GRID grid.137628.9, ISNI 0000 0004 1936 8753, Center for Biomedical Imaging (CBI), Center for Advanced Imaging Innovation and Research (CAI2R), Department of Radiology, , NYU Grossman School of Medicine, ; New York, NY USA
                Article
                29991
                10.1038/s41598-023-29991-1
                9945648
                36810898
                a8a36cf3-bd3b-440c-bcd9-6657722cc253
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 1 July 2022
                : 14 February 2023
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000002, National Institutes of Health;
                Award ID: 5P30CA016087
                Award ID: R01CA160620
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2023

                Uncategorized
                prognostic markers,preclinical research,cancer imaging,cancer metabolism,cancer microenvironment,tumour biomarkers,tumour heterogeneity,cancer therapy

                Comments

                Comment on this article